Format

Send to

Choose Destination
J Alzheimers Dis. 2018;64(1):291-302. doi: 10.3233/JAD-180126.

Honokiol Alleviates Cognitive Deficits of Alzheimer's Disease (PS1V97L) Transgenic Mice by Activating Mitochondrial SIRT3.

Li H1, Jia J1,2,3,4,5,6, Wang W1,2,3,4,5,6, Hou T1, Tian Y1, Wu Q2,3,4,5,6, Xu L1,2,3,4,5,6, Wei Y1,2,3,4,5,6, Wang X1.

Author information

1
Innovation Center for Neurological Disorders, Department of Neurology, Xuan Wu Hospital, Capital Medical University, Beijing, P.R. China.
2
Beijing Key Laboratory of Geriatric Cognitive Disorders, Beijing, P.R. China.
3
Clinical Center for Neurodegenerative Disease and MemoryImpairment, Capital Medical University, Beijing, P.R. China.
4
Center of Alzheimer's Disease, Beijing Institute for Brain Disorders, Beijing, P.R. China.
5
Key Laboratory of Neurodegenerative Diseases, Ministry of Education, Beijing, P.R. China.
6
National Clinical Research Center forGeriatric Disorders, Beijing, P.R. China.

Abstract

Accumulating evidence has demonstrated that mitochondrial dysfunction is a prominent early event in the progression of Alzheimer's disease (AD). Whether protecting mitochondrial function can reduce amyloid-β oligomer (AβO)-induced neurotoxicity in PS1V97L transgenic mice remains unknown. In this study, we examined the possible protective effects of honokiol (HKL) on mitochondrial dysfunction induced by AβOs in neurons, and cognitive function in AD PS1V97Ltransgenic mice. We determined that HKL increased mitochondrial sirtuin 3 (SIRT3) expression levels and activity, which in turn markedly improved ATP production and weakened mitochondrial reactive oxygen species production. We demonstrated that the enhanced energy metabolism and attenuated oxidative stress of HKL restores AβO-mediated mitochondrial dysfunction in vitro and in vivo. Consequently, memory deficits in the PS1V97L transgenic mice were rescued by HKL in the early stages. These results suggest that HKL has therapeutic potential for delaying the onset of AD symptoms by alleviating mitochondrial impairment and increasing hyperactivation of SIRT3 in the pathogenesis of preclinical AD.

KEYWORDS:

Alzheimer’s disease; amyloid-β protein; cognitive dysfunction; mitochondria; sirtuin 3 (SIRT3)

PMID:
29865070
DOI:
10.3233/JAD-180126
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for IOS Press
Loading ...
Support Center